Advertisement
Canada markets open in 6 hours 21 minutes

  • S&P/TSX

    22,011.72
    +139.76 (+0.64%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CAD/USD

    0.7313
    -0.0007 (-0.10%)
     

  • CRUDE OIL

    83.58
    +0.22 (+0.26%)
     

  • Bitcoin CAD

    91,283.45
    +458.00 (+0.50%)
     

  • CMC Crypto 200

    1,417.66
    -6.44 (-0.45%)
     

  • GOLD FUTURES

    2,339.20
    -2.90 (-0.12%)
     

  • RUSSELL 2000

    2,002.64
    +35.17 (+1.79%)
     

  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     

  • NASDAQ futures

    17,727.00
    +120.25 (+0.68%)
     

  • VOLATILITY

    15.69
    -1.25 (-7.38%)
     

  • FTSE

    8,044.81
    0.00 (0.00%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • CAD/EUR

    0.6838
    +0.0002 (+0.03%)
     

SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Trevena, Inc. - TRVN

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / October 17, 2018 / Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Trevena, Inc. (TRVN) from May 2, 2016 through October 8, 2018, inclusive (the ''Class Period''). The lawsuit seeks to recover damages for Trevena investors under the federal securities laws.

To join the Trevena class action, go to http://pawarlawgroup.com/cases/trevena-inc/ or call Vik Pawar, Esq. toll-free at 888-589-9804 or email vik@pawarlawgroup.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Trevena misled its shareholders into believing that its April 28, 2016 End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (''FDA'') for its drug candidate, Oliceridine, was far more successful than it actually was; (2) the FDA did not agree with the proposed dosing in the Phase 3 studies, the proposed primary endpoint, and the proposed non-inferiority margin for comparing morphine to Oliceridine; and (3) as a result, defendants' public statements were materially false and misleading at all relevant times. On this news, shares of Trevena plummeted $1.91 per share, or over 64%, to close at $1.07 per share on October 9, 2018.

ADVERTISEMENT

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 10, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://pawarlawgroup.com/cases/trevena-inc/ or to discuss your rights or interests regarding this class action, please contact Vik Pawar, Esq. of Pawar Law Group toll free at 888-589-9804 or via e-mail at vik@pawarlawgroup.com.

Pawar Law Group represents investors from around the world.

CONTACT:

Vik Pawar, Esq.
Pawar Law Group P.C
20 Vesey Street Suite 1210
New York, NY 10007
Tel: (917) 261-2277
Toll Free: 888-589-9804
Fax: (212) -571-0938
vik@pawarlawgroup.com
www.pawarlawgroup.com

SOURCE: Pawar Law Group